• About Merz Aesthetics

    Humans have always sought beauty, putting time, effort, skill and artistry into finding solutions to enhance natural beauty and prevent signs of aging. As a division of Merz Pharma Group, Merz Aesthetics is deeply devoted to the art of aesthetics.

    Read more

    Building on more than a century of healthcare expertise and scientific legacy, we offer one of the most comprehensive product portfolios in the aesthetics market.

    Read more
  • Dedicated to the development of botulinum neurotoxin for therapeutic use

    For patients with movement disorders, botulinum neurotoxin is often the treatment of choice. Merz´s expertise in this area has produced the only botulinum neurotoxin free from complexing proteins.

    Read more

    We are constantly working to advance new treatment standards and improve the quality of research, education and patient care.

    Read more
  • What do people really need?

    That was the key question of Friedrich Merz.

    The mindset of company founder Friedrich Merz continues to guide Merz today. In everything we do, our goal is to make a significant contribution to human well-being.

    Read more

    Merz has set itself an ambitious vision for the coming years focusing on two pillars: Aesthetics and Neurotoxins.

    Read more
  • Foster growth and create value

    Merz offers funding in early stage projects from emerging companies or academic institutions. In addition to our financial investment, we also offer provision of expertise.

    Read more

    As a leading international Aesthetics company we plan to invest globally in aesthetic healthcare companies pursuing innovative, breakthrough science.

    Read more

We envision new ways to improve the lives of our patients all over the world.

Latest News

Merz Pharma announces new investment in Cytrellis Biosystems

Frankfurt am Main /

Merz Pharma has made a strategic venture investment in Cytrellis Biosystems, a US based company developing a new class of non-surgical products to combat sagging skin associated with aging. Merz…

Read more

Merz Announces European Approval of Bocouture for the Treatment of Upper Facial Lines

Frankfurt am Main /

Merz Pharma Group today announced that Bocouture®  has been approved by European regulatory authorities for the treatment of upper facial lines, including horizontal frown lines, lateral periorbital lines and glabellar…

Read more

Merz Announces Nationwide Availability of New 200-Unit Vial of Xeomin®

Frankfurt / Raleigh, N.C., USA /

Merz North America (U.S. affiliate of the global Merz Pharma Group), today announced the nationwide availability of Xeomin® (incobotulinumtoxinA) in a 200-unit single-dose vial. This new dosage size supports the…

Read more

E-Mail

* mandatory fields

Please note that if you submit information to Merz all materials submitted by electronic or physical communication will be deemed non-confidential. Do not submit any information or other materials that you consider to be confidential or proprietary. While we have no intention to publicly disclose any details of your proposal, we may refer to select experts within or outside the Merz network for evaluation.